KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy

(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading

Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response)

(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading

KEI, UACT, UAEM, and SSW Appeal NIH Grant of Exclusive Licenses on CAR Cancer Therapy to Gilead/Kite

On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading